

# World Journal of *Clinical Cases*

*World J Clin Cases* 2019 October 26; 7(20): 3168-3383



**OPINION REVIEW**

- 3168** Clinical use of low-dose aspirin for elders and sensitive subjects  
*Zhang Y, Fang XM, Chen GX*

**ORIGINAL ARTICLE****Retrospective Study**

- 3175** Distribution and drug resistance of pathogenic bacteria in emergency patients  
*Huai W, Ma QB, Zheng JJ, Zhao Y, Zhai QR*
- 3185** Comparative analysis of robotic *vs* laparoscopic radical hysterectomy for cervical cancer  
*Chen L, Liu LP, Wen N, Qiao X, Meng YG*
- 3194** Feasibility of laparoscopic isolated caudate lobe resection for rare hepatic mesenchymal neoplasms  
*Li Y, Zeng KN, Ruan DY, Yao J, Yang Y, Chen GH, Wang GS*
- 3202** Rh-incompatible hemolytic disease of the newborn in Hefei  
*Bi SH, Jiang LL, Dai LY, Zheng H, Zhang J, Wang LL, Wang C, Jiang Q, Liu Y, Zhang YL, Wang J, Zhu C, Liu GH, Teng RJ*
- 3208** Soft tissue release combined with joint-sparing osteotomy for treatment of cavovarus foot deformity in older children: Analysis of 21 cases  
*Chen ZY, Wu ZY, An YH, Dong LF, He J, Chen R*

**Observational Study**

- 3217** Clinical characteristics of sentinel polyps and their correlation with proximal colon cancer: A retrospective observational study  
*Wang M, Lu JJ, Kong WJ, Kang XJ, Gao F*

**Prospective Study**

- 3226** Longitudinal observation of intraocular pressure variations with acute altitude changes  
*Xie Y, Sun YX, Han Y, Yang DY, Yang YQ, Cao K, Li SN, Li X, Lu XX, Wu SZ, Wang NL*

**Randomized Controlled Trial**

- 3237** Combination of propofol and dezocine to improve safety and efficacy of anesthesia for gastroscopy and colonoscopy in adults: A randomized, double-blind, controlled trial  
*Li XT, Ma CQ, Qi SH, Zhang LM*

**META-ANALYSIS**

- 3247** Prognostic significance of malignant ascites in gastric cancer patients with peritoneal metastasis: A systemic review and meta-analysis  
*Zheng LN, Wen F, Xu P, Zhang S*

**CASE REPORT**

- 3259** Gonadotrophin-releasing hormone agonist-induced pituitary adenoma apoplexy and casual finding of a parathyroid carcinoma: A case report and review of literature  
*Triviño V, Fidalgo O, Juane A, Pombo J, Cordido F*
- 3267** Constrictive pericarditis as a cause of refractory ascites after liver transplantation: A case report  
*Bezjak M, Kocman B, Jadrijević S, Gašparović H, Mrzljak A, Kanižaj TF, Vujanić D, Bubalo T, Mikulić D*
- 3271** Endoluminal closure of an unrecognized penetrating stab wound of the duodenum with endoscopic band ligation: A case report  
*Kim DH, Choi H, Kim KB, Yun HY, Han JH*
- 3276** Spontaneous superior mesenteric artery dissection following upper gastrointestinal panendoscopy: A case report and literature review  
*Ou Yang CM, Yen YT, Chua CH, Wu CC, Chu KE, Hung TI*
- 3282** Hepatic amyloidosis leading to hepatic venular occlusive disease and Budd-Chiari syndrome: A case report  
*Li TT, Wu YF, Liu FQ, He FL*
- 3296** De Winter syndrome and ST-segment elevation myocardial infarction can evolve into one another: Report of two cases  
*Lin YY, Wen YD, Wu GL, Xu XD*
- 3303** Next generation sequencing reveals co-existence of hereditary spherocytosis and Dubin-Johnson syndrome in a Chinese girl: A case report  
*Li Y, Li Y, Yang Y, Yang WR, Li JP, Peng GX, Song L, Fan HH, Ye L, Xiong YZ, Wu ZJ, Zhou K, Zhao X, Jing LP, Zhang FK, Zhang L*
- 3310** Recognizable type of pituitary, heart, kidney and skeletal dysplasia mostly caused by SEMA3A mutation: A case report  
*Hu F, Sun L*
- 3322** Repeated lumps and infections: A case report on breast augmentation complications  
*Zhang MX, Li SY, Xu LL, Zhao BW, Cai XY, Wang GL*
- 3329** Severe mental disorders following anti-retroviral treatment in a patient on peritoneal dialysis: A case report and literature review  
*He QE, Xia M, Ying GH, He XL, Chen JH, Yang Y*

- 3335** Fish bone-induced myocardial injury leading to a misdiagnosis of acute myocardial infarction: A case report  
*Wang QQ, Hu Y, Zhu LF, Zhu WJ, Shen P*
- 3341** Potentially fatal electrolyte imbalance caused by severe hydrofluoric acid burns combined with inhalation injury: A case report  
*Fang H, Wang GY, Wang X, He F, Su JD*
- 3347** Ureter - an unusual site of breast cancer metastasis: A case report  
*Zhou ZH, Sun LJ, Zhang GM*
- 3353** Alternative technique to save ischemic bowel segment in management of neonatal short bowel syndrome: A case report  
*Geng L, Zhou L, Ding GJ, Xu XL, Wu YM, Liu JJ, Fu TL*
- 3358** Sister Mary Joseph's nodule in endometrial carcinoma: A case report  
*Li Y, Guo P, Wang B, Jia YT*
- 3364** Synchronous quadruple primary malignancies of the cervix, endometrium, ovary, and stomach in a single patient: A case report and review of literature  
*Wang DD, Yang Q*
- 3372** Ureteral Ewing's sarcoma in an elderly woman: A case report  
*Li XX, Bi JB*
- 3377** Anaplastic lymphoma kinase-negative anaplastic large cell lymphoma masquerading as Behcet's disease: A case report and review of literature  
*Luo J, Jiang YH, Lei Z, Miao YL*

**ABOUT COVER**

Editorial Board Member of *World Journal of Clinical Cases*, Faycal Lakhdar, MD, Professor, Department of Neurosurgery, University Hospital Center of Fes, University Sidi Mohammed Ben Abdellah, FES 10000, Morocco

**AIMS AND SCOPE**

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

**INDEXING/ABSTRACTING**

The WJCC is now indexed in PubMed, PubMed Central, Science Citation Index Expanded (also known as SciSearch®), and Journal Citation Reports/Science Edition. The 2019 Edition of Journal Citation Reports cites the 2018 impact factor for WJCC as 1.153 (5-year impact factor: N/A), ranking WJCC as 99 among 160 journals in Medicine, General and Internal (quartile in category Q3).

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Responsible Electronic Editor: Ji-Hong Liu

Proofing Production Department Director: Yun-Xiaojuan Wu

**NAME OF JOURNAL**

*World Journal of Clinical Cases*

**ISSN**

ISSN 2307-8960 (online)

**LAUNCH DATE**

April 16, 2013

**FREQUENCY**

Semimonthly

**EDITORS-IN-CHIEF**

Dennis A Bloomfield, Bao-Gan Peng, Sandro Vento

**EDITORIAL BOARD MEMBERS**

<https://www.wjnet.com/2307-8960/editorialboard.htm>

**EDITORIAL OFFICE**

Jin-Lei Wang, Director

**PUBLICATION DATE**

October 26, 2019

**COPYRIGHT**

© 2019 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjnet.com/bpg/gerinfo/240>

**PUBLICATION MISCONDUCT**

<https://www.wjnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



## Severe mental disorders following anti-retroviral treatment in a patient on peritoneal dialysis: A case report and literature review

Qi-En He, Min Xia, Guang-Hui Ying, Xue-Lin He, Jiang-Hua Chen, Yi Yang

**ORCID number:** Qi-En He (0000-0002-4189-0519); Min Xia (0000-0001-8554-9913); Guang-Hui Ying (0000-0002-0522-1676); Xue-Lin He (0000-0001-9301-3705); Jiang-Hua Chen (0000-0002-9539-000X); Yi Yang (0000-0002-6285-0807).

**Author contributions:** Yang Y performed the investigation and provided resources for the case care and report; Xia M, Ying GH collected the patient's clinical data; He XL analyzed data; He QE wrote the first draft of the article; Chen JH and Yang Y reviewed and edited the article for important intellectual content.

**Supported by** the grant from the National Nature Science Foundation of China, No. 81670621; and the Nature Science Foundation of Zhejiang Province, No. LY16H050001.

**Informed consent statement:** Consent was obtained from relatives of the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in

Qi-En He, Xue-Lin He, Jiang-Hua Chen, Yi Yang, Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province, the Third Grade Laboratory Under the National State, Administration of Traditional Chinese Medicine, Hangzhou 310000, Zhejiang Province, China

Qi-En He, Min Xia, Guang-Hui Ying, Xue-Lin He, Department of Nephrology, Beilun People's Hospital, Ningbo 315000, Zhejiang Province, China

**Corresponding author:** Yi Yang, MD, Doctor, Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province; the Third Grade Laboratory under the National State, Administration of Traditional Chinese Medicine, Hangzhou 310000, Zhejiang Province, China. [zjukidney@zju.edu.cn](mailto:zjukidney@zju.edu.cn)  
**Telephone:** +86-571-87236992

### Abstract

#### BACKGROUND

Antiviral drugs are widely used in populations with viral infection caused by immunologic inadequacy. Because these drugs are mainly metabolized by the kidneys, patients with renal failure undergoing renal replacement therapy are prone to drug adverse effects and poisoning. Severe neurotoxicity caused by antiviral drugs is a rare but life-threatening complication.

#### CASE SUMMARY

This study reported one male patient on peritoneal dialysis who suffered from severe mental disorders after receiving an overdose of acyclovir and valacyclovir for the treatment of herpes zoster. The literature review suggested that hemodialysis is better than peritoneal dialysis to clear acyclovir from the circulation. The patient died after his consciousness deteriorated despite peritoneal dialysis and continuous blood purification.

#### CONCLUSION

This case emphasizes cautiousness when using anti-retroviral drugs in patients with uremia. Hemodialysis is optimal method to remove the drugs.

**Key words:** Chronic renal failure; Peritoneal dialysis; Acyclovir; Valacyclovir; Neurotoxicity; Herpes zoster; Case report

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.



accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Received:** May 29, 2019

**Peer-review started:** June 4, 2019

**First decision:** August 1, 2019

**Revised:** August 23, 2019

**Accepted:** September 11, 2019

**Article in press:** September 11, 2019

**Published online:** October 26, 2019

**P-Reviewer:** Hatipoglu S

**S-Editor:** Wang JL

**L-Editor:** Ma JY

**E-Editor:** Qi LL



**Core tip:** A patient on peritoneal dialysis who received an overdose of anti-virals showed severe mental disorders. Peritoneal dialysis and continuous renal replacement therapy did not improve the symptoms. Hemodialysis is recommended to remove excess drugs.

**Citation:** He QE, Xia M, Ying GH, He XL, Chen JH, Yang Y. Severe mental disorders following anti-retroviral treatment in a patient on peritoneal dialysis: A case report and literature review. *World J Clin Cases* 2019; 7(20): 3329-3334

**URL:** <https://www.wjnet.com/2307-8960/full/v7/i20/3329.htm>

**DOI:** <https://dx.doi.org/10.12998/wjcc.v7.i20.3329>

## INTRODUCTION

Herpes zoster occurs upon reactivation of varicella zoster virus and is characterized by pain and blistering skin eruption with dermatomal distribution<sup>[1-4]</sup>. The occurrence of herpes zoster increases with decline in T-cell-mediated immunity, which may occur with age or immunosuppression<sup>[1-4]</sup>. The rash typically resolves in 2-4 wk, but nerve pain may continue for months to years<sup>[1,3]</sup>. Beside pain management, anti-retroviral drugs can be used in patients without response to topical anti-retroviral, age  $\geq 50$  years, moderate to severe pain, severe rash, and/or non-truncal involvement<sup>[2,4]</sup>. The common drugs include valacyclovir, acyclovir, foscarnet, and brivudine<sup>[2]</sup>. Compared with acyclovir, valacyclovir has advantages such as better oral effectiveness and tolerance, high water solubility, and less adverse reactions. Valacyclovir rapidly transforms into acyclovir after entering the body. Its common side effects include nausea, vomiting, and discomfort<sup>[5]</sup>.

One possible, albeit rare, side effect of anti-retroviral drugs is central nervous system toxicity, which has been described since the 1980s<sup>[6-9]</sup>. The symptoms in patients with previously normal brain function may include visual hallucinations, death delusion, tremor, and coma, with onset of 24-72 h after starting acyclovir<sup>[8]</sup>. The symptoms are possibly due to a metabolite of acyclovir that is found at high levels in the cerebrospinal fluid of patients with neuropsychiatric symptoms<sup>[10]</sup>. Since 90% of acyclovir is cleared by the kidneys, patients with chronic kidney disease have increased serum half-life of acyclovir<sup>[11]</sup>. Most patients with neuropsychiatric disorders under acyclovir treatment have renal function impairment<sup>[10]</sup>.

We present one patient on peritoneal dialysis who suffered from severe mental disorders after taking an overdose of antiviral drugs for herpes zoster. The patient died after his consciousness did not improve after peritoneal dialysis and continuous blood purification.

## CASE PRESENTATION

### Chief complaints

A 65-year-old man on peritoneal dialysis was referred to our hospital in July 2018 with complaints of blisters on the left frontal area with pain, and unstable walking and hallucinations.

### History of present illness

The patient felt severe pain in the left frontal face, with blisters for 6 d, and was diagnosed with herpes zoster. He was given antiviral treatment with intravenous acyclovir 0.5 g qd and dexamethasone 5 mg qd to relieve pain (continuous treatment for 3 d). The dermatologist prescribed oral valacyclovir 0.3 g bid after 3 d. Nonetheless, the patient misunderstood the recommendation, and received acyclovir and valacyclovir simultaneously. After 2 d of treatment, the local facial pain was relieved, and the blisters became stable, but he became with unstable walking and involuntary shaking of the limbs, accompanied by hallucinations (irregular fluttering of objects when the eyes were closed), irritability, and lethargy. He denied fever, loss of consciousness, epilepsy, suicidal or homicidal ideation, and a sudden stop of dialysis. Before onset, the patient had mild temperament and took care of himself in the daily life.

### History of past illness

The patient had a history of hypertension for more than 10 years, under control using

nifedipine controlled release tablets 30 mg bid and valsartan 80 mg bid.

He was diagnosed with idiopathic chronic renal failure (stage 5). He had been receiving peritoneal dialysis treatment for 3 years. He was anuric at admission using peritoneal dialysis solution with 2.5% calcium glucose 2000 mL × 4 bags, continuous ambulatory peritoneal dialysis (CAPD), with an ultrafiltration of 1200 mL/d.

### **Personal and family history**

The patient denied any personal or family history of diseases.

### **Physical examination upon admission**

On admission, the body temperature 37.2 °C, pulse 107 bpm, breathing 20/min, blood pressure 175/108 mmHg, intermittent mild disturbance of consciousness, and with visible scattered red blister rash in the left eyelid and left forehead, which was protruded and tender, but otherwise with normal superficial lymph nodes and cardiopulmonary examinations. Nervous system examination showed negative Pap's sign but normal muscle tension in limbs.

### **Laboratory examinations**

The laboratory examinations showed: White blood cells  $7.8 \times 10^9/L$ , hemoglobin 86 g/L, albumin 28 g/L, creatinine 1146  $\mu\text{mol/L}$ , urea nitrogen 21.6 mmol/L, uric acid 277  $\mu\text{mol/L}$ , potassium 4.2 mmol/L, sodium 145 mmol/L, chlorine 100 mmol/L,  $\text{PO}_2$  43 mmHg,  $\text{TCO}_2$  24 mmol/L, glucose 4.7 mmol/L, and iPTH 313 pg/mL. Dialysis adequacy:  $\text{KT}/V = 1.64$  (1 mo ago),  $\text{Ccr} = 41.4 \text{ L/wk}$ . The electrocardiogram showed normal sinus rhythm. The lumbar puncture showed: Cerebrospinal fluid pressure 155 mmH<sub>2</sub>O, proteins 542 mg/L, glucose 4.64 mmol/L, chlorine 121.7 mmol/L (no abnormality), and negative bacteria and tuberculosis.

### **Imaging examinations**

There were no obvious abnormalities in head and chest computed tomography (CT) as well as head magnetic resonance imaging (MRI).

---

## **FINAL DIAGNOSIS**

Based on the laboratory test results and imaging examinations, the differential diagnoses of cerebrovascular accidents, viral encephalitis and uremia encephalopathy were ruled out. Since he had a clear history of overdose of antiviral drugs 6 days prior to the onset of the psychiatric symptoms, the patient was finally diagnosed as mental disorders caused by antiviral drugs.

---

## **TREATMENT**

Immediately after admission, valacyclovir was discontinued, the peritoneal fluid was increased to 5 bags/d, 2000 mL per bag, and CAPD mode, and the blood pressure was dropped to around 150-160/90 mmHg after antihypertensive treatment with Adalat 30 mg bid, valsartan 80 mg bid and perindopril 8 mg qd. After 2 d of treatment, the involuntary limb shaking was not relieved and the disturbance of consciousness progressively aggravated (drowsiness-delirium-coma). On the third day after admission (July 31, 2018), the patient's respiratory failure worsened, blood gas analysis showed: pH 7.18,  $\text{PO}_2$  81 mmHg (oxygen), and  $\text{PaCO}_2$  77 mmHg, revealing carbon dioxide retention and type 2 respiratory failure. After intubation and respiratory support, the patient was transferred to the intensive care unit (ICU) on the fourth day after admission. In the ICU, peritoneal dialysis was discontinued and continuous renal replacement therapy (CRRT) was started.

---

## **OUTCOME AND FOLLOW-UP**

Though given positive rescue treatment, the patient's consciousness was not improved. The patient died 6 d after admission.

---

## **DISCUSSION**

Herpes zoster usually develops in patients with compromised immune function. Patients on dialysis are at high risk of Herpes zoster. Both valacyclovir and acyclovir



are considered to have strong inhibitory effects on types 1 and 2 herpes virus and varicella herpes virus<sup>[12]</sup>. Valacyclovir is a precursor of acyclovir, which is converted to acyclovir by the liver. Compared with acyclovir, it has the advantages of higher absorption rate, more better pharmacokinetics and pharmacodynamics, and lower frequency of use<sup>[5]</sup>.

The neurotoxicity of acyclovir was reported as early as the 1980s<sup>[6-9]</sup>. The clinical manifestations include consciousness disorders and hallucinations, fantasy, insomnia, photoallergies, dysarthria, paresthesia, and coma<sup>[13-17]</sup>. If uremia patients develop neuropsychiatric symptoms during anti-retroviral treatment, it is especially important to promptly identify and discontinue the suspicious drugs. Clinicians tend to overlook drug-induced neuropsychiatric disorders. The patient had a history of excessive use of antiviral drugs and showed obvious neuropsychiatric symptoms, despite normal head CT and MRI, and lumbar puncture and cerebrospinal fluid examination. In the present report, the patient had limb shaking, visual hallucinations, and severe disturbances of consciousness, and these symptoms progressively aggravated, which is very rare.

Valacyclovir-associated neurotoxicity usually occurs within 48-72 h of treatment start, and the symptoms can be gradually relieved after the drug is discontinued for 4-14 d (Table 1). For the patient in the present study, the time of onset and duration of symptoms were similar to those reported in literature<sup>[14,16-25]</sup> (Table 1).

Since acyclovir is mainly cleared by the kidneys, it is a consensus to reduce its dose in patients with renal failure<sup>[25]</sup>. The dose is mainly determined by a combination of factors such as different methods of dialysis, residual renal function, hydration, and age. The dose of drug used in many cases of neurotoxicity is often greater than the recommended dose<sup>[11,24]</sup>. It is generally believed that a concentration of acyclovir of 2.5-4.5 µg/mL<sup>[26]</sup> or a concentration of its main metabolite, carboxymethoxy methylguanine, above 10.8 µmol/L<sup>[10]</sup> in plasma leads to neurotoxicity. Nevertheless, there is still no consensus on the specific numerical reference range of therapeutic and toxic doses of such drugs, and it is difficult to measure the drug levels in clinical practice.

In the case reported here, increasing the dose of peritoneal dialysis and retention time still could not alleviate the clinical symptoms. Acyclovir and valacyclovir are both soluble and low-protein-bound drugs. In terms of the effectiveness of valacyclovir, a single hemodialysis for 6 h can remove about 60% of the drug, while it is considered to have poor clearance by peritoneal dialysis. On the other hand, case reports suggested that peritoneal dialysis with continuous perfusion of super-dose peritoneal dialysis solution can promote the clearance of valacyclovir<sup>[13,21,24,27]</sup>. Studies have shown that in patients with normal renal function, 89% of valacyclovir can be cleared from the urine in the form of acyclovir after 2.5-3.3 h, while the half-life of the drug is extended to 14-20 h in patients receiving CAPD for uremia (4 × 2 L exchange dose), and only 5.27 mL/min (0.355 L/h/1.73 m<sup>2</sup>) can be cleared by peritoneal dialysis<sup>[21,27]</sup>. After a 6-h hemodialysis, the hemodialysis clearance rate of acyclovir is up to 113 mL/min and the plasma drug concentration can be reduced by 61.6%. Therefore, hemodialysis is at least 20 times better than peritoneal dialysis in terms of clearance effect. Based on the large differences in clearance rates between the two dialysis methods, it is suggested to switch peritoneal dialysis to hemodialysis to increase the effect of drug clearance<sup>[20,24,28]</sup>. Nevertheless, when neurotoxicity occurs, the expected improvement of neurotoxicity by hemodialysis may be delayed, even for a few days. Kageyama *et al*<sup>[29]</sup> reported a 75-year-old hemodialysis male who presented with hallucinations, dysarthria, and psychotic symptoms after intravenous acyclovir with reduced dose, which further indicates that the dose adjustment of these drugs is difficult and needs to be comprehensively individualized. CRRT has a good effect on clearing drugs with middle-and-large molecular weight or high protein binding rate. Meanwhile, valacyclovir and acyclovir are soluble and have a low protein binding rate, but there is a lack of literature on the efficacy of CRRT in clearing acyclovir and valacyclovir.

## CONCLUSION

In summary, clinicians need to be extra cautious when applying antiviral drugs in patients with renal failure. They need to be alert to the possible serious neuropsychiatric symptoms, need to adjust dose according to the level of renal function, pay attention to treatment course and hydration, be fully aware of the possible neurotoxicity caused by these drugs, and be aware of the good prognosis after early identification and active intervention. In the meantime, since the clearance rate of these drugs is low when using peritoneal dialysis, these patients should be

**Table 1** The reported cases of acyclovir/valacyclovir neurotoxicity in the literature

Author	Year of publication	Patient sex/age	Stage of CKD	Renal replacement manner	Dosage (mg/d)	Duration of antiviral treatment	Concomitant medication	Neuropsychiatric symptoms	Outcome
Pipili <i>et al</i> <sup>[18]</sup>	2013	Female/72	ESRD	PD	Valacyclovir tablets 3 g daily for 3 d	3 d	Nifedipine, irbesartan, cinacalcet, atorvastatin, alfacalcidol	Confusion and visual hallucinations	3 d, restored after PD 6 × 2 L per day
Chaudhari <i>et al</i> <sup>[16]</sup>	2014	Male/66	ESRD	PD	Oral valacyclovir 1000 mg daily for 7 d	7 d	Simvastatin, metoprolol, sevelamer, furosemide, and glimepiride	Hallucination, insomnia, and photosensitivity	7 d, improved after regular regimen and hydration
Asahi <i>et al</i> <sup>[17]</sup>	2009	Female/78	Without previous renal failure	NO	Valacyclovir 3000 mg/d	6 d	Not mentioned	Unconsciousness	5 d, recovered 14 d later
Asahi <i>et al</i> <sup>[17]</sup>	2009	Male/73	ESRD	Hemodialysis	Valacyclovir 3000 mg/d	2 d	Not mentioned	Confusion, hallucination	2 d, completely recovered 3 d later
Singh <i>et al</i> <sup>[19]</sup>	2014	Female/58	ESRD	HD	Valacyclovir 500 mg/d	2 d	Not mentioned	Altered sensorium, irritability, drowsiness, confusion	2 d, completely recovered 5 d later
Kambhampati <i>et al</i> <sup>[20]</sup>	2011	Female/49	ESRD	Maintenance hemodialysis	Valacyclovir 1000 mg three times a day	2 d	Not mentioned	Disoriented, confused, agitated, hallucinating, delirious, incoherent	1 d, 4000 mg, completely recovered after second session of hemodialysis
Prasad <i>et al</i> <sup>[14]</sup>	2017	Female/57	ESRD	PD	1000mg three times per day of valacyclovir	3 d	Not mentioned	Confusion and altered sensorium	1 day, completely recovered 24h later
Izzedine <i>et al</i> <sup>[21]</sup>	2001	Female/60	ESRD	PD	Valacyclovir 500 mg daily	Reduced 500 mg of valacyclovir every 2 d	Not mentioned	Disorientated with ocular and auditory hallucinations and loss of decorum without torpor or coma.	3 d, recovered 48 h later
Strumia <i>et al</i> <sup>[22]</sup>	2004	Male/81	ESRD	Hemodialysis	Oral valacyclovir 1000 mg every 8 h then intravenous acyclovir in full dosage	3 d	Not mentioned	Visual hallucination, confusion and disorientation	3 daysd completely recovered 6 d later
Linssen-Schuurmans <i>et al</i> <sup>[23]</sup>	1998	Male/58	CKD	Intermittent hemodialysis twice a week	Valacyclovir 3 g/d	2 d	Not mentioned	Dizziness, hallucinations , loss of decorum, disoriented, slurred speech	1 d, complete recovery
Takayanagi <i>et al</i> <sup>[24]</sup>	2010	Male/67	ESRD	PD	Valacyclovir, 1 g/d	5 d	Not mentioned	Hallucinations	7 d, complete recovery
Sadjadi <i>et al</i> <sup>[25]</sup>	2018	Male/80	ESRD	PD	Acyclovir 5 mg/kg intravenously , followed by oral acyclovir 400 mg/d	3 d	Not mentioned	Confusion, delusion, disorientation , restlessness, visual hallucinations , seizures	2 d, complete recovery

CKD: Chronic kidney disease; ESRD: End-stage renal disease; PD: Peritoneal dialysis.

switched to hemodialysis.

## REFERENCES

- 1 **Sampathkumar P**, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. *Mayo Clin Proc* 2009; **84**: 274-280 [PMID: [19252116](#) DOI: [10.1016/S0025-6196\(11\)61146-4](#)]
- 2 **Cohen JI**. Clinical practice: Herpes zoster. *N Engl J Med* 2013; **369**: 255-263 [PMID: [23863052](#) DOI: [10.1056/NEJMcpr1302674](#)]
- 3 **Wilson JF**. In the clinic. Herpes zoster. *Ann Intern Med* 2011; **154**: ITC31-15; quiz ITC316 [PMID: [21357905](#) DOI: [10.7326/0003-4819-154-5-201103010-01003](#)]
- 4 **Dworkin RH**, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpaa ML, McKendrick MW, Nurmikko TJ, Oaklander AL, Oxman MN, Pavan-Langston D, Petersen KL, Rowbotham MC, Schmader KE, Stacey BR, Tyring SK, van Wijck AJ, Wallace MS, Wassilew SW, Whitley RJ. Recommendations for the management of herpes zoster. *Clin Infect Dis* 2007; **44** Suppl 1: S1-26 [PMID: [17143845](#) DOI: [10.1086/510206](#)]
- 5 **Cernik C**, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. *Arch Intern Med* 2008; **168**: 1137-1144 [PMID: [18541820](#) DOI: [10.1001/archinte.168.11.1137](#)]
- 6 **Wade JC**, Meyers JD. Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation. *Ann Intern Med* 1983; **98**: 921-925 [PMID: [6305245](#)]
- 7 **Cohen SM**, Minkove JA, Zebley JW, Mulholland JH. Severe but reversible neurotoxicity from acyclovir. *Ann Intern Med* 1984; **100**: 920 [PMID: [6721312](#)]
- 8 **Tomson CR**, Goodship TH, Rodger RS. Psychiatric side-effects of acyclovir in patients with chronic renal failure. *Lancet* 1985; **2**: 385-386 [PMID: [2862533](#)]
- 9 **Vartian CV**, Shlaes DM. Intravenous acyclovir and neurologic effects. *Ann Intern Med* 1983; **99**: 568 [PMID: [6625395](#)]
- 10 **Helldén A**, Odar-Cederlöf I, Diener P, Barkholt L, Medin C, Svensson JO, Säwe J, Ståhle L. High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanidine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study. *Nephrol Dial Transplant* 2003; **18**: 1135-1141 [PMID: [12748346](#)]
- 11 **Haefeli WE**, Schoenenberger RA, Weiss P, Ritz RF. Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose. *Am J Med* 1993; **94**: 212-215 [PMID: [8430717](#)]
- 12 **Lin WR**, Lin HH, Lee SS, Tsai HC, Huang CK, Wann SR, Chen YS, Chiang SC, Yen MY, Liu YC. Comparative study of the efficacy and safety of valacyclovir versus acyclovir in the treatment of herpes zoster. *J Microbiol Immunol Infect* 2001; **34**: 138-142 [PMID: [11456360](#)]
- 13 **Okada T**, Nakao T, Matsumoto H, Nagaoka Y, Iwasawa H, Nanri K, Yamazaki T. Valacyclovir neurotoxicity in a patient with end-stage renal disease treated with continuous ambulatory peritoneal dialysis. *Clin Nephrol* 2002; **58**: 168-170 [PMID: [12227692](#)]
- 14 **Prasad B**, McIsaac M, Toppings J. Valacyclovir-associated neurotoxicity treated with intensification of peritoneal dialysis. *BMJ Case Rep* 2017; **2017**: bcr-2017-220678 [PMID: [28765478](#) DOI: [10.1136/bcr-2017-220678](#)]
- 15 **Olin JL**, Gugliotta JL. Possible valacyclovir-related neurotoxicity and aseptic meningitis. *Ann Pharmacother* 2003; **37**: 1814-1817 [PMID: [14632597](#) DOI: [10.1345/aph.1D171](#)]
- 16 **Chaudhari D**, Ginn D. Valacyclovir-associated neurotoxicity in peritoneal dialysis patients. *Am J Ther* 2014; **21**: e215-e217 [PMID: [23528373](#) DOI: [10.1097/MJT.0b013e318289bae9](#)]
- 17 **Asahi T**, Tsutsui M, Wakasugi M, Tange D, Takahashi C, Tokui K, Okazawa S, Okudera H. Valacyclovir neurotoxicity: clinical experience and review of the literature. *Eur J Neurol* 2009; **16**: 457-460 [PMID: [19187258](#) DOI: [10.1111/j.1468-1331.2008.02527.x](#)]
- 18 **Pipili C**, Pantelias K, Deda E, Tsiamalos P, Kostis E, Grapsa E. Intensification of peritoneal dialysis improves valacyclovir neurotoxicity. *Ren Fail* 2013; **35**: 289-290 [PMID: [23176110](#) DOI: [10.3109/0886022x.2012.743914](#)]
- 19 **Singh NP**, Shah HR, Aggarwal N, Jha LK, Behura S. Valacyclovir associated neurotoxicity in a patient on dialysis. *Indian J Nephrol* 2014; **24**: 128-129 [PMID: [24701050](#) DOI: [10.4103/0971-4065.127915](#)]
- 20 **Kambhampati G**, Pakkivenkata U, Kazory A. Valacyclovir neurotoxicity can be effectively managed by hemodialysis. *Eur J Neurol* 2011; **18**: e33 [PMID: [21087359](#) DOI: [10.1111/j.1468-1331.2010.03250.x](#)]
- 21 **Izzedine H**, Mercadal L, Aymard G, Launay-Vacher V, Martinez V, Issad B, Deray G. Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study. *Am J Nephrol* 2001; **21**: 162-164 [PMID: [11359026](#) DOI: [10.1159/000046241](#)]
- 22 **Strumia S**, De Mitri P, Bionda E. Neurotoxicity of acyclovir and valacyclovir in a hemodialyzed patient. *Eur J Neurol* 2004; **11**: 68-69 [PMID: [14692893](#)]
- 23 **Linssen-Schuurmans CD**, van Kan EJ, Feith GW, Uges DR. Neurotoxicity caused by valacyclovir in a patient on hemodialysis. *Ther Drug Monit* 1998; **20**: 385-386 [PMID: [9712461](#)]
- 24 **Takayanagi A**, Maehana T, Kyoda Y, Yanase M. [Neurotoxicity of valacyclovir in a peritoneal dialysis patient]. *Hinyokika Kiyo* 2010; **56**: 617-619 [PMID: [21187705](#)]
- 25 **Sadjadi SA**, Regmi S, Chau T. Acyclovir Neurotoxicity in a Peritoneal Dialysis Patient: Report of a Case and Review of the Pharmacokinetics of Acyclovir. *Am J Case Rep* 2018; **19**: 1459-1462 [PMID: [30531673](#) DOI: [10.12659/AJCR.911520](#)]
- 26 **Feldman S**, Rodman J, Gregory B. Excessive serum concentrations of acyclovir and neurotoxicity. *J Infect Dis* 1988; **157**: 385-388 [PMID: [3335815](#)]
- 27 **Stathouloupoulou F**, Dhillon S, Thodis H, Stathakis C, Vargemezis V. Evaluation of valaciclovir dosage reduction in continuous ambulatory peritoneal dialysis patients. *Nephron* 2002; **91**: 164-166 [PMID: [12021536](#) DOI: [10.1159/000057621](#)]
- 28 **Takayanagi A**, Hashimoto J, Adachi H, Horita H. Two patients with neurotoxicity caused by over-dose of antiviral drugs during hemodialysis therapy. *Jpn J Clin Neurol* 2006; **60**: 581-583
- 29 **Kageyama R**, Hashizume H. Neurotoxicity induced by the recommended acyclovir dosing in a dialysis patient with herpes zoster: A case letter. *J Dermatol* 2016; **43**: 339-340 [PMID: [26589129](#) DOI: [10.1111/1346-8138.13196](#)]



Published By Baishideng Publishing Group Inc  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
Telephone: +1-925-2238242  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

